ArticleNeurology2024
Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children.
Abstract readValidation Study
In one paragraph
Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Beyond Positivity: Understanding and Interpreting MOG-IgG Testing in MOGAD.Journal of clinical neurology (Seoul, Korea) · 2026Review
- Reports of the Clinician's Demise Are Greatly Exaggerated: Clinical Judgment Remains Key in Diagnosing MOGAD.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Article
- MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology.European journal of neurology · 2026Article
- Clinical and laboratory findings in patients with anti-myelin oligodendrocyte glycoprotein antibodies: experience from two tertiary hospitals in Madrid.Frontiers in immunology · 2026Article
- Neurological graft-versus-host disease with MOG antibody positivity after allogeneic stem cell transplantation: a case report.Frontiers in immunology · 2026Article
- Neuromyelitis optica spectrum disorder overlapping with Sjögren's disease: immunopathological links and therapeutic implications.Frontiers in immunology · 2026Review
- Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.Therapeutic advances in neurological disorders · 2026Article
- Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.Seminars in respiratory and critical care medicine · 2025Review
- Late-onset myelin oligodendrocyte glycoprotein antibody-associated disease: an underrecognized entity in clinical practice; what does its course in later life teach us? A case report and narrative review.Postepy psychiatrii neurologii · 2025Article
- Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Observational
- Diversity, Functional Complexity, and Translational Potential of Glial Cells in the Central Nervous System.International journal of molecular sciences · 2025Review
- Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders.Neurology(R) neuroimmunology & neuroinflammation · 2025Observational
- Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Neurology · 2025Observational
- Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Review
- Confusing Onset of MOGAD in the Form of Focal Seizures.Neurology international · 2025Article
- Performance of the 2023 diagnostic criteria for MOGAD: real-world application in a Chinese multicenter cohort of pediatric and adult patients.BMC medicine · 2025Article
- The influence of MOGAD on diagnosis of multiple sclerosis using MRI.Nature reviews. Neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
James A VarleyFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0009-0009-8338-8859
Dimitrios ChampsasFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0002-7275-4982
Timothy ProssorFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Giuseppe PontilloFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0001-5425-1890
Omar Abdel-MannanFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0002-0796-9645
Zhaleh KhaleeliFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Axel PetzoldFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0002-0344-9749
Ahmed T ToosyFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0002-4441-3750
Sachid A TripFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Heather WilsonFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Dermot H MallonFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0001-7434-1201
Cheryl HemingwayFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0002-3899-3015
Kshitij MankadFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0001-5979-9337
Michael Kin Loon ChouFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0009-0001-5067-4113
Andrew J ChurchFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0009-0009-4562-0338
Melanie S HartFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Michael P LunnFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0003-3174-6027
Wallace BrownleeFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0003-0481-8902
Yael HacohenFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0001-8490-9657
Olga CiccarelliFrom the Queen Square MS Centre (J.A.V., G.P., O.A.-M., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., C.H., M.S.H., W.B., Y.H., O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London; Department of Brain Sciences (J.A.V.), Charing Cross Hospital, Imperial College London; Department of Neurology (D.C., O.A.-M., C.H., Y.H.), Great Ormond Street Hospital for Children; The National Hospital for Neurology and Neurosurgery (T.P., Z.K., A.P., A.T.T., S.A.T., H.W., D.H.M., M.S.H., M.P.L., W.B., O.C.), UCLH NHS Trust, London, United Kingdom; Neuro-ophthalmology Expert Centre (A.P.), Amsterdam UMC, the Netherlands; Moorfields Eye Hospital NHS Foundation Trust (A.P.); Department of Radiology (K.M.), Great Ormond Street Hospital for Children; Neuroimmunology and CSF Laboratory (M.K.L.C., A.J.C., M.S.H., M.P.L.), National Hospital for Neurology and Neurosurgery; National Institute for Health and Care Research (NIHR) (M.S.H., M.P.L., W.B., O.C.), University College London Hospitals Biomedical Research Centre; and Department of Neuromuscular Diseases (M.P.L.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID 0000-0001-7485-1367
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTo test the performance of the 2023 myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) criteria in adults and children with inflammatory demyelinating conditions who were tested for MOG antibodies (Abs).
methodsThis was a retrospective study of patients tested for MOG-Abs from 2018 to 2022 in 2 specialist hospitals. The inclusion criteria comprised ≥1 attendance in an adult or pediatric demyelinating disease clinic and complete clinical and MRI records. The final clinical diagnosis of MOGAD, made by the treating neurologist, was taken as the benchmark against which the new criteria were tested. The international MOGAD diagnostic criteria were applied retrospectively; they stipulate at least 1 clinical or MRI supporting feature for MOGAD diagnosis in positive fixed MOG cell-based assay without a titer. The performance MOG-Ab testing alone for MOGAD diagnosis was also assessed and compared with that of MOGAD criteria using the McNemar test.
resultsOf the 1,879 patients tested for MOG-Abs, 539 (135 pediatric and 404 adults) met the inclusion criteria. A clinical diagnosis of MOGAD was made in 86/539 (16%) patients (37 adults, 49 children), with a median follow-up of 3.6 years. The MOGAD diagnostic criteria had sensitivity of 96.5% (adults 91.9%, children 100%), specificity of 98.9% (adults 98.8%, children 98.9%), positive predictive value of 94.3% (adults 89.4%, children 98%), negative predictive value of 99.3% (adults 99.2%, children 100%), and accuracy of 98.5% (adults 98.3%, children 99.2%). When compared with MOG-Ab testing alone, a difference was seen only in adults: a significantly higher specificity (98.9% vs 95.6%, DISCUSSION: The international MOGAD diagnostic criteria exhibit high performance in selected patients with inflammatory demyelinating diseases (who had a high pretest probability of having MOGAD) compared with best clinical judgment; their performance was better in children than in adults. In adults, the MOGAD criteria led to an improvement in specificity and positive predictive value when compared with MOG-Ab testing alone, suggesting that the requirement of at least 1 clinical or MRI supporting feature is important. Future work should address the generalizability of the diagnostic criteria to cohorts of greater clinical diversity seen within neurologic settings.
Indexed as
AutoantibodiesMyelin-Oligodendrocyte GlycoproteinAdolescentAdultAgedChildChild, PreschoolCohort StudiesFemaleHumansInfantMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesSensitivity and SpecificityAutoantibodiesMOG protein, humanMyelin-Oligodendrocyte Glycoprotein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.